CNBX Pharmaceuticals hires Vilki & Co. as auditor

Q: Who is CNBX's new independent accounting firm?

CNBX engaged Vilki & Co. on September 28, 2026 as its new independent accounting firm, as of and for the year ended August 31, 2026.

Q: Why did CNBX change its independent auditor?

CNBX said the change was not the result of a disagreement with Elkana Amitai CPA. It also reported no disagreements on accounting, disclosure or audit-scope matters and no reportable events during the years ended August 31, 2025 and 2026 through September 28, 2026.

CNBX reported no auditor disagreements or reportable events through September 28, 2026; its fiscal 2024 and 2025 audit reports included going-concern paragraphs.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

CNBX Pharmaceuticals Inc. dismissed Elkana Amitai CPA as its independent registered public accounting firm effective September 28, 2026, and engaged Vilki & Co. on that date as its new independent accounting firm as of and for the year ended August 31, 2026. CNBX said the change was not the result of a disagreement. It reported no disagreements or reportable events during the years ended August 31, 2025 and 2026 through the dismissal date. The former firm's audit reports for the fiscal years ended August 31, 2024 and 2025 included explanatory paragraphs indicating substantial doubt about CNBX's ability to continue as a going concern; the reports contained no adverse or disclaimer opinions and were not otherwise qualified or modified.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

1 major · 1 point

How the balance works

Positive

None.

Negative

Major pointGoing-concern doubt appeared in 2024 and 2025 audit reports.

8-K Event Classification

2 items: 4.01, 9.01

2 items

Item 4.01 Changes in Registrant's Certifying Accountant Governance

The company changed its independent auditing firm, which may involve disagreements on accounting matters.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Former auditor dismissal effective date: September 28, 2026 New auditor engagement date: September 28, 2026 New auditor engagement period: Year ended August 31, 2026 +1 more

4 metrics

Former auditor dismissal effective date September 28, 2026 Effective date of the dismissal

New auditor engagement date September 28, 2026 Date CNBX engaged Vilki & Co.

New auditor engagement period Year ended August 31, 2026 Period stated for the new accounting firm

Fiscal years with going-concern paragraphs Years ended August 31, 2024 and August 31, 2025 Former auditor's reports included explanatory paragraphs indicating substantial doubt about CNBX's ability to continue as a going concern

Key Terms

independent registered public accounting firm, going concern, reportable events, adverse opinion

4 terms

independent registered public accounting firm technical

"as its independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

going concern financial

"substantial doubt about the Company's ability to continue as a going concern"

Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

reportable events regulatory

"no “reportable events”"

Reportable events are significant incidents or changes a company is legally required to disclose to regulators and the public, such as major safety problems, legal actions, financial irregularities, or management changes. They matter to investors because these events can alter a company’s risk profile or future performance, much like a dashboard warning light signals a problem that could affect a car’s safety or reliability. Timely disclosure helps investors make informed decisions and maintain market fairness.

adverse opinion technical

"did not contain an adverse opinion"

An adverse opinion is an auditor’s formal conclusion that a company’s financial statements contain serious errors or omissions and therefore cannot be relied upon as a true picture of the business. For investors it’s a major red flag—like a mechanic saying a car is unsafe—because it signals heightened risk of fraud, restatements, regulatory trouble or loss of access to capital, any of which can sharply affect share value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is CNBX's new independent accounting firm?

CNBX engaged Vilki & Co. on September 28, 2026 as its new independent accounting firm, as of and for the year ended August 31, 2026.

Why did CNBX change its independent auditor?

CNBX said the change was not the result of a disagreement with Elkana Amitai CPA. It also reported no disagreements on accounting, disclosure or audit-scope matters and no reportable events during the years ended August 31, 2025 and 2026 through September 28, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/01/2026 - 02:09 PM Accepted by SEC EDGAR 10/01/2026 - 02:09 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 28, 2026

CNBX PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Nevada	000-52403	20-3373669
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

#3 Bethesda Metro Center

Suite 700

Bethesda, MD 20814

(Address of principal executive offices and Zip Code)

877 424-2429

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CNBX		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01

Changes in Registrant's Certifying Accountant

The Board of Directors of CNBX Pharmaceuticals Inc. (the “Company”) has dismissed Elkana Amitai CPA (“Former Accounting Firm”) as its independent registered public accounting firm, effective as of September 28th, 2026. As described in Item 4.01(a) below, the change in independent registered public accounting firm is not the result of any disagreement with the Former Accounting Firm. The Board made the decision to dismiss the Former Accounting Firm acting under authority delegated to it and the Board of Directors approved the same on September 28th, 2026. On the same date, the Board of Directors of the Company engaged Vilki & Co-#1 Luxor Palace, Gandhi Smruti Bhavan, Gujarat, India 394651 (the “New Accounting Firm”) as its new independent accounting firm as of and for the year ended August 31^st, 2026.

The Former Accounting Firm's audit reports on the Company's consolidated financial statements as of and for the fiscal years ended August 31^st, 2024 and 2025 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that Former Accounting Firm's reports, on the Company’s consolidated financial statements as of and for the fiscal years ended August 31^st, 2024 and 2025included an explanatory paragraph indicating that there was substantial doubt about the Company’s ability to continue as a going concern.

During the years ended August 31, 2025 and 2026, and through the Dismissal Date, there were (i) no disagreements between the Company and Former Accounting Firm Elkana Amitai CPA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreement, if not resolved to the satisfaction of Elkana Amitai CPA, would have caused them to make reference thereto in their reports on the consolidated financial statements for such years, and (ii) no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K

The Company has not consulted with the New Accounting Firm during our two most recent fiscal years or during any subsequent interim period prior to its appointment as New Accounting Firm regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on our financial statements, and neither a written report was provided to us nor oral advice was provided that the New Accounting Firm concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (within the meaning of Item 304(a)(1)(v) of Regulation S-K).

The Company has requested that the Former Accounting Firm furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statement. A copy of the letter from the Former Accounting Firm is attached hereto as Exhibit 16.1 to this Form 8-K

Item 9.01

Financial Statements & Exhibits

(d) Exhibits

Exhibit Number		Description

16.1		Letter from Elkana Amitai CPA

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CNBX Pharmaceuticals Inc.


Date: October 1, 2026	By:	/s/ Eyal Barad
		Eyal Barad
		Director, CEO

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents